Compare · BLCO vs COO
BLCO vs COO
Side-by-side comparison of Bausch + Lomb Corporation (BLCO) and The Cooper Companies Inc. (COO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BLCO and COO operate in Ophthalmic Goods (Health Care), so they compete in similar markets.
- COO is the larger of the two at $19.03B, about 3.1x BLCO ($6.16B).
- BLCO has hit the wire 23 times in the past 4 weeks while COO has been quiet.
- COO has more recent analyst coverage (25 ratings vs 19 for BLCO).
- Company
- Bausch + Lomb Corporation
- The Cooper Companies Inc.
- Price
- $17.26-0.29%
- $73.07-3.59%
- Market cap
- $6.16B
- $19.03B
- 1M return
- -
- +3.97%
- 1Y return
- -
- -0.87%
- Industry
- Ophthalmic Goods
- Ophthalmic Goods
- Exchange
- NYSE
- NYSE
- IPO
- 2022
- News (4w)
- 23
- 0
- Recent ratings
- 19
- 25
Bausch + Lomb Corporation
Bausch + Lomb Corporation operates as an eye health company in Canada and internationally. It operates through three segments: Vision Care, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that cover the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products, over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions comprising eye allergies, conjunctivitis, and dry eye. The Ophthalmic Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment glaucoma, ocular hypertension, and retinal diseases; and contact lenses for therapeutic use. The Surgical segment provides tools and technologies for the treatment of cataracts, and vitreous and retinal eye conditions. It offers intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices. The company was founded in 1853 and is headquartered in Vaughan, Canada.
The Cooper Companies Inc.
The Cooper Companies, Inc. operates as a medical device company worldwide. It operates through two segments, CooperVision and CooperSurgical. The company develops, manufactures, and markets a range of contact lenses, including spherical lenses, and toric and multifocal lenses that correct near- and farsightedness, as well as addresses various complex visual defects, such as astigmatism and presbyopia. It also provides range of products and services for enhancing health of women, babies, and families, including medical devices, fertility, genomics, and diagnostics and contraception for hospitals and surgical centers, obstetricians' and gynecologists' (OB/GYNs) medical offices, and fertility clinics. In addition, the company develops mechanical surgical solutions for skin closure; and offers PARAGARD, a contraceptive, as well as provides assisted reproductive technology products, genetic screening and testing, and products within the general OB/GYN offerings. It markets its products under Biofinity, clariti 1day, MyDay, Avaira Vitality, and Proclear 1 Day brand name through a network of field sales representatives, independent agents, eye care practitioners, and distributors. The Cooper Companies, Inc. was founded in 1980 and is headquartered in San Ramon, California.
Latest BLCO
- Bausch + Lomb Advancing Two First-in-Class Eye Health Therapies Based on Trial Results
- Director Trebbi Barbara was granted 11,776 shares (SEC Form 4)
- SEC Form 3 filed by new insider Trebbi Barbara
- Director Paul Laurence E was granted 11,776 shares (SEC Form 4)
- SEC Form 3 filed by new insider Paul Laurence E
- Director Chersi Robert J was granted 11,776 shares (SEC Form 4)
- SEC Form 3 filed by new insider Chersi Robert J
- New insider Appio Thomas claimed ownership of 27,583 shares (SEC Form 3)
- SVP, Controller and CAO Munsch Frederick sold $887,662 worth of shares (52,900 units at $16.78), decreasing direct ownership by 54% to 45,831 units (SEC Form 4)
- Amendment: SEC Form 8-K/A filed by Bausch + Lomb Corporation
Latest COO
- CooperCompanies Announces Release Date for Third Quarter 2026
- UBS initiated coverage on Cooper with a new price target
- SEC Form 4 filed by Director Keel Paul A
- SEC Form 3 filed by new insider Keel Paul A
- CooperSurgical Supports Saving Mothers to Help Advance Global Women’s Health and Raise Awareness
- CooperCompanies Releases 2025 Corporate Sustainability Report with Scope 3 Emissions Disclosure
- SEC Form 10-Q filed by The Cooper Companies Inc.
- Needham reiterated coverage on Cooper with a new price target
- SEC Form 8-K filed by The Cooper Companies Inc.
- CooperCompanies Announces Second Quarter 2026 Results